Loading clinical trials...
Loading clinical trials...
A Phase 1b, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Oral Administration of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) And Hyperoxaluria
Conditions
Interventions
BMN 255
Placebo
Locations
7
United States
University of Alabama - Department of Urology
Birmingham, Alabama, United States
ProSciento, Inc.
Chula Vista, California, United States
ProSciento, Inc.
Chula Vista Isles, Florida, United States
Georgia Clinical Research, LLC
Lawrenceville, Georgia, United States
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
Centricity Research
Columbus, Ohio, United States
Start Date
September 26, 2023
Primary Completion Date
March 25, 2024
Completion Date
March 25, 2024
Last Updated
June 11, 2024
NCT07237750
NCT04603898
NCT07055282
NCT05334979
NCT04580420
NCT07297953
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions